Top

Published in:

01-03-2021 | Hemophilia | News item

HPRA: potential emicizumab interference with blood coagulation tests

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Ireland's HPRA¹ is raising awareness of the potential risk of incorrect results due to sample-to-sample contamination with emicizumab (Hemlibra) when undertaking blood coagulation tests. …

HPRA = Health Products Regulatory Authority

CE marking is the medical device manufacturer's claim that a product meets the essential requirements of all relevant European Medical Device Directives.

Health Products Regulatory Authority. Emicizumab (Hemlibra) interference with blood coagulation tests - Priority 2 - Warning. Internet Document : 25 Feb 2021. Available from: URL: https://www.hpra.ie/homepage/medical-devices/safety-information/safety-notices

Title: HPRA: potential emicizumab interference with blood coagulation tests
Publication date: 01-03-2021
Publisher: Springer International Publishing
Keyword: Hemophilia
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-92250-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HPRA: potential emicizumab interference with blood coagulation tests

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Alemtuzumab/immune globulin

Rituximab/unspecified steroids

Sevoflurane

Antineoplastics

Prednisolone/steroids

Immune-globulin/rituximab/tacrolimus